More than 450 biomedical executives have joined a new online membership organisation, the Biomedical Executive Forum
More than 450 biomedical executives have joined a new online membership organisation, the Biomedical Executive Forum.
New members include vice presidents and product managers at major research and diagnostic firms, as well as CEOs and CSOs at early-stage biotechnology companies.
Stock research analysts, venture capitalists and consultants are also well represented among the recent registrations.
While there are numerous professional and industry groups associated with the life sciences, there is no single association, conference or event designed to facilitate the exchange of knowledge between executives wrestling with the daily challenges of managing their businesses in a fast changing market.
Designed as a one-stop-shop for information that is critical to these busy professionals, the Biomedical Executive Forum was launched to fill this void. "We are very excited by the formation of this new organisation," says Matt Scherer, associate director of the Biomedical Executive Forum.
"I think the hundreds of membership applications received on the first day validates our belief that executives in biomedical companies have been looking for a peer-to-peer resource that will help their companies compete more effectively.
"We're well on our way to making the Biomedical Executive Forum the premier internet portal for credible, accurate and quality information about the biomedical industry" The information on the organisation's website is not limited to that currently being contributed by its members in the form of articles, website links, book review and online discussions.
"The next step is to deliver industry 'best practices' reports, professional development programs and biomedical market statistics that will only be available to registered members," says Scherer.
The group plans to launch its first benchmark study on the current performance of the biomedical industry.
"The industry is experiencing great convergence between biotech, diagnostic and therapeutic technologies and this has tremendous implications for how companies are positioned, organised and managed," notes Scherer.
"Executives in each of these segments face common challenges and by surveying our members on a wide variety of management issues, we can report back to them which strategies and business processes appear to be most successful among companies in specific markets.
"This data also forms the basis of the professional development programs we're developing that are specifically tailored to the unique demands of our market."
